<DOC>
	<DOCNO>NCT00058994</DOCNO>
	<brief_summary>The purpose study demonstrate anecortave acetate superior placebo maintenance visual acuity 12- 24-month visit .</brief_summary>
	<brief_title>An Evaluation Safety Efficacy Anecortave Acetate Versus Placebo Patients With Subfoveal CNV Due Exudative AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<criteria>Patients least 50 year age , race , either sex clinical diagnosis exudative AMD primary recurrent subfoveal CNV lesion study eye .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>AMD</keyword>
	<keyword>anecortave acetate</keyword>
	<keyword>wet AMD</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Maculopathy , Age-Related</keyword>
	<keyword>Age-Related Maculopathies</keyword>
	<keyword>Age-Related Maculopathy</keyword>
	<keyword>Maculopathies , Age-Related</keyword>
</DOC>